All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, June 30, 2022
Home » Blogs » BioWorld Perspectives » A $100B Market Cap: Now That’s a Big Deal for Biotech

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld

A $100B Market Cap: Now That’s a Big Deal for Biotech

Oct. 9, 2013
By Peter Winter
No Comments

BRemember the heady days about eight years ago when Amgen Inc. and Genentech Inc., prior to its acquisition by Basel, Switzerland-based Roche AG, both vied for top spot in terms of market capitalization? At that time, both companies briefly commanded impressive $100 billion market caps and their collective valuation represented a significant chunk of the whole sector’s worth. Between then and now the industry took a nose dive in the wake of cratering global financial markets. As a result valuations declined and Genentech, now a unit of Roche, no longer factors into the industry’s current performance statistics.

Well, thanks to an amazing run that the sector has been on for almost 24 months the prestigious $100 billion market cap is again within sight.

It might have been attained, too, but for the U.S. government shutdown and looming debt ceiling uncertainties that have spooked the markets putting biotech valuations on a reverse trajectory as company stock prices fall.

We will have to wait and just marvel at the numbers that were put up by biotech. Prior to the government machinations, Gilead Sciences Inc. reached a market cap of almost $97 billion with Amgen Inc. not too far behind sporting a market cap of $88 billion.

The difference between the Amgen/Genentech era and now is the fact that the gap between the valuations of Gilead/Amgen and other “blue chip” biotechs is not as wide as it was back then when Amgen/Genentech represented almost 50 percent of the total sector’s value.

The incredible performances that many firms have been exhibiting on the capital markets have served to drive the sector to lofty new valuation heights – more than $500 billion at the end of the third quarter.

According to our ongoing analysis, 54 biotech companies developing therapeutics, with market caps greater than $1 billion, collectively saw their share prices jump by an average of 27 percent and finished up by a whopping 92 percent at the close of the third quarter.

The statistics are equally impressive when the 257 public biotechnology companies that are developing biotherapeutics are taken into account. According to the BioWorld Stock Report, they collectively recorded an average 28 percent share price increase in the quarter and a 51 percent increase since the beginning of the year.

This stellar performance may become a distant memory if the shutdown in Washington drags on for a significant period. Already the biotech sector has slipped 6 percent since the end of the quarter giving fuel to those pundits who believe that the industry’s “bubble” has burst.

I am not in that camp. This is a mere temporary hiatus as investors take the opportunity to lock in profits from biotech’s great run. The fundamental underpinnings of the sector are still strong and while biotech’s “run” may slow down to a “trot” during the fourth, it is still on a trajectory for even higher valuations in 2014.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 29, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for June 29.
  • Enhertu.png

    Swing low, sweet Enhertu: Astrazeneca, Daiichi ASCO data carry HER2 message home

    BioWorld
    The “showdown” at the American Society of Clinical Oncology (ASCO) meeting foreseen by one analyst between breast cancer drugs from Gilead Sciences Inc. and...
  • Novavax-COVID-19-vaccine-vial

    Novavax vaccine shows its chops

    BioWorld
    Given that Novavax Inc.’s COVID-19 vaccine will be a latecomer to the U.S. scene if it gets FDA authorization, it’s been cast in a supporting role to the lead...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing